Guanidinium phosphate (1:1)

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

03JAN2013 to 24JAN2013

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2013

Report date:

2013

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)

Deviations:

no

Test guideline 3

Qualifier:

according to guideline

Guideline:

EPA OPPTS 870.1100 (Acute Oral Toxicity)

Deviations:

no

Test guideline 4

Qualifier:

according to guideline

Guideline:

other: Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF), 2011, including the most recent partial revisions.

Deviations:

no

GLP compliance:

yes

Test type:

acute toxic class method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Guanidinium phosphate (1:1)

EC Number:

226-551-9

EC Name:

Guanidinium phosphate (1:1)

Cas Number:

5423-22-3

Molecular formula:

CH8N3O4P

IUPAC Name:

(diazaniumylmethylidene)azanium phosphate

Test material form:

solid: crystalline

Details on test material:

- Name of test material (as cited in study report): Guanidine phosphate (1:1)
- Physical state: White crystal solid
- CAS no.: 5423-22-3
- Storage condition of test material: In refrigerator (2-8°C) in the dark in well-sealed container
- pH: 5 at concentration of 50%

Test animals

Species:

rat

Strain:

other: Crl:WI (Han)

Sex:

female

Details on test animals or test system and environmental conditions:

- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: Young adult animals (approx. 8-12 weeks old)
- Weight at study initiation: Body weight variation was within +/- 20% of the sex mean (150-203g)
- Fasting period before study: yes, overnight
- Housing: Group housing of 3 animals per cage in labeled Macrolon cages
- Diet: Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany)
- Water: Free access to tap water
- Acclimation period: At least 5 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18 – 24
- Humidity (%): 40 - 70
- Air changes (per hr): approx 15
- Photoperiod (hrs dark / hrs light): 12/12

IN-LIFE DATES: From: 03JAN2013 to 24JAN2013

Administration / exposure

Route of administration:

oral: gavage

Details on oral exposure:

GAVAGE METHOD: plastic feeding tubes.

Frequency: single dosage, on Day 1.

VEHICLE: water
- Justification for choice of vehicle: The vehicle was selected based on trial formulations performed at WIL Research Europe and on test substance data supplied by the sponsor.

MAXIMUM DOSE VOLUME APPLIED: 2000 mg/kg (10 mL/kg) body weight.

DOSAGE PREPARATION: The formulations (w/w) were prepared within 4 hours prior to dosing. Homogeneity was accomplished to a visually acceptable level. No correction was made for purity of the test substance. The concentration of the test substance in vehicle was varied to allow constant dosage volume in terms of mL/kg body weight.

Doses:

2000 or 300 mg/kg body weight

No. of animals per sex per dose:

2000 mg/kg bw: 3
300 mg/kg bw: 6 (2 groups of three females in a stepwise manner)

Control animals:

no

Details on study design:

The toxicity of the test substance was assessed by stepwise treatment of groups of 3 females. The first group was treated at a dose level of 2000 mg/kg. The absence or presence of mortality of animals dosed at one step determined the next step, based on the test procedure defined in the guidelines. The onset, duration and severity of the signs of toxicity were taken into account for determination of the time interval between the dose groups.

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Mortality/Viability: Twice daily
Body weights: Days 1 (pre-administration), 8 and 15
Clinical signs: At periodic intervals on the day of dosing (Day 1) and once daily thereafter, until Day 15.
- Necropsy of survivors performed: The animals surviving to the end of the observation period were sacrificed by oxygen/carbon dioxide procedure. All animals assigned to the study were subjected to necropsy and descriptions of all internal macroscopic abnormalities recorded
- Other examinations performed: none

Statistics:

No statistical analysis was performed (The method used is not intended to allow the calculation of a precise LD50 value).

Results and discussion

Effect levels

Sex:

female

Dose descriptor:

LD50

Effect level:

> 300 - < 2 000 mg/kg bw

Based on:

test mat.

Mortality:

Three female were found dead on Day 1. No further mortality occurred.

Clinical signs:

other: At a dose level of 2000 mg/kg bw the following clinical signs were noted: Lethargy, tremor, abnormal posture, flat and/or hunched posture, abnormal gait, piloerection, restless and fearful behavior and/or chromodacryorrhoea were noted on Day one (day of d

Gross pathology:

Macroscopic post mortem examination of the animals at 2000 mg/kg (that were all found dead on Day 1) revealed in two animals: several reddish foci in the glandular mucosa of the stomach and/or gastro-intestinal tract distended with gas.
No abnormalities were found at macroscopic post mortem examination of the animals at 300 mg/kg.

Applicant's summary and conclusion

Interpretation of results:

harmful

Remarks:

Migrated information cat. 4 Criteria used for interpretation of results: EU

Conclusions:

In an acute oral toxicity study with rats, performed according to OECD/EC test guidelines and GLP principles, an LD50 between 300 and 2000 mg/kg bw for Guanidinium phosphate (1:1) was determined.

Executive summary:

An acute oral toxicity study was performed with rats according to OECD/EC test guidelines and GLP principles following the acute toxic class method. Three rats were exposed to 2000 mg/kg bw guanidinium phosphate (1:1), all three died on day 1. Lethargy, tremor, abnormal posture, flat and/or hunched posture, abnormal gait, piloerection, restless and fearful behavior and/or chromodacryorrhoea were noted on the day of death. Macroscopic post mortem examination of these animals revealed in two animals several reddish foci in the glandular mucosa of the stomach and/or gastro-intestinal tract distended with gas.

Two groups of three rats were exposed to 300 mg/kg bw, no further mortality occurred. Three animals showed hunched posture and piloerection on Day 1, no abnormalities were found at necropsy. The body weight gain shown by the surviving animals over the study period was considered to be similar to that expected of normal untreated animals of the same age and strain.

Based on these data, the LD50 for guanidinium phosphate (1:1) was determined to be between 300 and 2000 mg/kg bw, the substance is classified for oral toxicity in category 4 according to Regulation (EC) 1272/2008.